PSTVbenzinga

D. Boral Capital Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $9

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 17, 2025 by benzinga